Qiu et al. reported a case of severe thrombocytopenia and anemia occurring after 4.5 months of atezolizumab, which proved refractory to various treatments, including injection of intravenous immunoglobulin (IVIG), thrombopoietin, and plasma exchange and resulted in the expiration of the patient [35]. This evidence concerns the gene THPO and Thrombocytopenia.